In the article titled "MSL-109 Adjuvant Therapy for Cytomegalovirus Retinitis in Patients With Acquired Immunodeficiency Syndrome" published in the December 1997 issue of the ARCHIVES (Arch Ophthalmol. 1997;115:1528-1536), the reported values for the "Increase in retinal area involved by CMV" given in the "Other Visual Outcomes" subsection on page 1532 and in Table 3 on page 1534 are incorrect. The correct values for the MSL-109 group, placebo group, and P are 1.49, 1.55, and .93, respectively.